Janus Kinase (JAK) inhibitors are small molecules that can be administrated orally. In addition, they are trouble free in reaching the inside of cells and inhibit intracellular signaling molecules directly.
The janus kinase (JAK) inhibitors market is expected to grow significantly during the forecast period due to rising prevalence of chronic and autoimmune diseases which includes life threatening disease like rheumatoid arthritis, psoria. The janus kinase (JAK) inhibitors market is segmented on the basis of drug class, indication and distribution channels.
The COVID 19 has already started to have an impact on janus kinase (JAK) inhibitors market. The worldwide lockdowns may have resulted in lowering the sales of the market in current situation. However, the janus kinase (JAK) inhibitorsmarket is expected to pick up the pace and may also grow substantially in the upcoming years.
The increasing prevalence of autoimmune andchronic diseases including rheumatic arthritis, psoriatic arthritis, ulcerative colitis etc. is expected to drive the growth of the Janus kinase (JAK) inhibitors market. Additionally, the increasing number of special designations for drugs in the pipeline is also expected to fuel the growth of the market.
However, the growth of januskinase (JAK) inhibitors market may be hindered by the cost of treatment and lack of funds in conducting research.
On the basis of drug class, the janus kinase (JAK) inhibitors market is segmented into baricitinib, tofacitinib, ruxolitinib and pipeline drugs. Tofacitinib and baricitinib are expected to continue to grow significantly in this segment due to their efficacy in treating the diseases.
On the basis of indication, the janus kinase (JAK) inhibitors market is segmented into rheumatoid arthritis, psoriatic arthritis, systemic lupus erythmatosus and others. In this segment rheumatoid arthritis is expected to be the highest contributor due to it’s growing prevalence.
On the basis of distribution channel, the janus kinase (JAK) inhibitors market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Retail pharmacies are expected to continue to contribute towards highest revenue in this segment.
Geographically, thejanus kinase (JAK) inhibitors marketis segmented into sevenregions viz.Asia Pacific, Europe,Latin America, North America, OceaniaandMiddle East and Africa. The North America is expected to lead the janus kinase (JAK) inhibitors market due to increased health expenses and availability of advanced medication.
Additionally, increasing awareness among the people about diseases is also a major factor that may boost the growth of the market in this region. Europe is expected to have the second largest market for global janus kinase (JAK) inhibitors.
However, Asia Pacific is anticipated to experience fastest growth in the janus kinase (JAK) inhibitors market as a result of increase in prevalence of chronic diseases. In the Middle East and Africa the market growth is expected to be limited due to slow economic growth, underdeveloped infrastructure and lower access to technological advancement.
Some of the players identified in the warm Janus kinase (JAK) inhibitors market include:
The global janus kinase (JAK) inhibitors markethas been segmented on the basis of drug class, indication and distribution channel.
drug class
indication
distribution channel
Explore Similar Insights
Janus Kinase (JAK) Inhibitors Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
